DIAGNOSTIC METHODS AND COMPOSITIONS FOR TREATING GLIOBLASTOMA Russian patent published in 2019 - IPC A61K39/00 

FIELD: biotechnology; medicine.

SUBSTANCE: invention refers to biotechnology and medicine and represents a method for determining whether a patient with glioblastoma is more likely to respond to a VEGF antagonist, wherein said method involves: (i) detecting the expression of NCAM1, OMG, PRKCZ, GALNT13, GPR17, DNM3, FERMT1, SNAP91, ABHD6 and PFN2 in a biological sample obtained from said patient, prior to administering to said patient a VEGF antagonist; and (ii) comparing the expression level of NCAM1, OMG, PRKCZ, GALNT13, GPR17, DNM3, FERMT1, SNAP91, ABHD6 and PFN2 with a reference expression level of NCAM1, OMG, PRKCZ, GALNT13, GPR17, DNM3, FERMT1, SNAP91, ABHD6 and PFN2, wherein increase in said expression level of NCAM1, OMG, PRKCZ, GALNT13, GPR17, DNM3, FERMT1, SNAP91, ABHD6 and PFN2 in a sample obtained from said patient relative to said reference expression level enables detecting a patient as having a proneural (PN) glioblastoma subtype and with high probability will respond to treatment with VEGF antagonist, wherein reference expression level is: (a) a median expression level of NCAM1, OMG, PRKCZ, GALNT13, GPR17, DNM3, FERMT1, SNAP91, ABHD6 and PFN2 in a population of patients having glioblastoma and undergoing analysis to determine susceptibility to a VEGF antagonist or (b) a median expression level of NCAM1, OMG, PRKCZ, GALNT13, GPR17, DNM3, FERMT1, SNAP91, ABHD6 and PFN2 in the patients having glioblastoma, which have been found to respond to the VEGF antagonist treatment.

EFFECT: invention enables determining an effective anticancer therapy in a patient having glioblastoma.

18 cl, 6 dwg, 6 tbl, 5 ex